NCT06045767View on ClinicalTrials.gov

T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

January 31, 2029

Study Completion Date

January 31, 2029

Conditions
Non-small Cell Lung Cancer Metastatic
Interventions
DRUG

Pembrolizumab 50 MG Injection [Keytruda]

Chemo-immunotherapy combination

All Listed Sponsors
collaborator

Bar-Ilan University, Israel

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Ari Raphael

OTHER

NCT06045767 - T-Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced Non-small Lung Cancer | Biotech Hunter | Biotech Hunter